238 related articles for article (PubMed ID: 30233647)
1. Computational Tools for Splicing Defect Prediction in Breast/Ovarian Cancer Genes: How Efficient Are They at Predicting RNA Alterations?
Moles-Fernández A; Duran-Lozano L; Montalban G; Bonache S; López-Perolio I; Menéndez M; Santamariña M; Behar R; Blanco A; Carrasco E; López-Fernández A; Stjepanovic N; Balmaña J; Capellá G; Pineda M; Vega A; Lázaro C; de la Hoya M; Diez O; Gutiérrez-Enríquez S
Front Genet; 2018; 9():366. PubMed ID: 30233647
[No Abstract] [Full Text] [Related]
2. Analysis of 30 putative BRCA1 splicing mutations in hereditary breast and ovarian cancer families identifies exonic splice site mutations that escape in silico prediction.
Wappenschmidt B; Becker AA; Hauke J; Weber U; Engert S; Köhler J; Kast K; Arnold N; Rhiem K; Hahnen E; Meindl A; Schmutzler RK
PLoS One; 2012; 7(12):e50800. PubMed ID: 23239986
[TBL] [Abstract][Full Text] [Related]
3. Targeted RNA-seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes.
Brandão RD; Mensaert K; López-Perolio I; Tserpelis D; Xenakis M; Lattimore V; Walker LC; Kvist A; Vega A; Gutiérrez-Enríquez S; Díez O; ; de la Hoya M; Spurdle AB; De Meyer T; Blok MJ
Int J Cancer; 2019 Jul; 145(2):401-414. PubMed ID: 30623411
[TBL] [Abstract][Full Text] [Related]
4. Role of Splicing Regulatory Elements and In Silico Tools Usage in the Identification of Deep Intronic Splicing Variants in Hereditary Breast/Ovarian Cancer Genes.
Moles-Fernández A; Domènech-Vivó J; Tenés A; Balmaña J; Diez O; Gutiérrez-Enríquez S
Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34283047
[TBL] [Abstract][Full Text] [Related]
5. Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary.
Whiley PJ; Guidugli L; Walker LC; Healey S; Thompson BA; Lakhani SR; Da Silva LM; ; Tavtigian SV; Goldgar DE; Brown MA; Couch FJ; Spurdle AB
Hum Mutat; 2011 Jun; 32(6):678-87. PubMed ID: 21394826
[TBL] [Abstract][Full Text] [Related]
6. Prioritizing Variants in Complete Hereditary Breast and Ovarian Cancer Genes in Patients Lacking Known BRCA Mutations.
Caminsky NG; Mucaki EJ; Perri AM; Lu R; Knoll JH; Rogan PK
Hum Mutat; 2016 Jul; 37(7):640-52. PubMed ID: 26898890
[TBL] [Abstract][Full Text] [Related]
7. Mis-splicing in breast cancer: identification of pathogenic BRCA2 variants by systematic minigene assays.
Fraile-Bethencourt E; Valenzuela-Palomo A; Díez-Gómez B; Goina E; Acedo A; Buratti E; Velasco EA
J Pathol; 2019 Aug; 248(4):409-420. PubMed ID: 30883759
[TBL] [Abstract][Full Text] [Related]
8. Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants.
Houdayer C; Caux-Moncoutier V; Krieger S; Barrois M; Bonnet F; Bourdon V; Bronner M; Buisson M; Coulet F; Gaildrat P; Lefol C; Léone M; Mazoyer S; Muller D; Remenieras A; Révillion F; Rouleau E; Sokolowska J; Vert JP; Lidereau R; Soubrier F; Sobol H; Sevenet N; Bressac-de Paillerets B; Hardouin A; Tosi M; Sinilnikova OM; Stoppa-Lyonnet D
Hum Mutat; 2012 Aug; 33(8):1228-38. PubMed ID: 22505045
[TBL] [Abstract][Full Text] [Related]
9. Minigene Splicing Assays Identify 12 Spliceogenic Variants of
Fraile-Bethencourt E; Valenzuela-Palomo A; Díez-Gómez B; Caloca MJ; Gómez-Barrero S; Velasco EA
Front Genet; 2019; 10():503. PubMed ID: 31191615
[TBL] [Abstract][Full Text] [Related]
10. Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2 genes.
Menéndez M; Castellsagué J; Mirete M; Pros E; Feliubadaló L; Osorio A; Calaf M; Tornero E; del Valle J; Fernández-Rodríguez J; Quiles F; Salinas M; Velasco A; Teulé A; Brunet J; Blanco I; Capellá G; Lázaro C
Breast Cancer Res Treat; 2012 Apr; 132(3):979-92. PubMed ID: 21735045
[TBL] [Abstract][Full Text] [Related]
11. Variant effect on splicing regulatory elements, branchpoint usage, and pseudoexonization: Strategies to enhance bioinformatic prediction using hereditary cancer genes as exemplars.
Canson D; Glubb D; Spurdle AB
Hum Mutat; 2020 Oct; 41(10):1705-1721. PubMed ID: 32623769
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of in silico splice tools for decision-making in molecular diagnosis.
Houdayer C; Dehainault C; Mattler C; Michaux D; Caux-Moncoutier V; Pagès-Berhouet S; d'Enghien CD; Laugé A; Castera L; Gauthier-Villars M; Stoppa-Lyonnet D
Hum Mutat; 2008 Jul; 29(7):975-82. PubMed ID: 18449911
[TBL] [Abstract][Full Text] [Related]
13. Identification of Spliceogenic Variants beyond Canonical GT-AG Splice Sites in Hereditary Cancer Genes.
Dragoš VŠ; Strojnik K; Klančar G; Škerl P; Stegel V; Blatnik A; Banjac M; Krajc M; Novaković S
Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806449
[TBL] [Abstract][Full Text] [Related]
14. Performance of in silico prediction tools for the classification of rare BRCA1/2 missense variants in clinical diagnostics.
Ernst C; Hahnen E; Engel C; Nothnagel M; Weber J; Schmutzler RK; Hauke J
BMC Med Genomics; 2018 Mar; 11(1):35. PubMed ID: 29580235
[TBL] [Abstract][Full Text] [Related]
15. Performance Evaluation of SpliceAI for the Prediction of Splicing of
Ha C; Kim JW; Jang JH
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573290
[TBL] [Abstract][Full Text] [Related]
16. Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members.
Thomassen M; Blanco A; Montagna M; Hansen TV; Pedersen IS; Gutiérrez-Enríquez S; Menéndez M; Fachal L; Santamariña M; Steffensen AY; Jønson L; Agata S; Whiley P; Tognazzo S; Tornero E; Jensen UB; Balmaña J; Kruse TA; Goldgar DE; Lázaro C; Diez O; Spurdle AB; Vega A
Breast Cancer Res Treat; 2012 Apr; 132(3):1009-23. PubMed ID: 21769658
[TBL] [Abstract][Full Text] [Related]
17. Functional classification of DNA variants by hybrid minigenes: Identification of 30 spliceogenic variants of BRCA2 exons 17 and 18.
Fraile-Bethencourt E; Díez-Gómez B; Velásquez-Zapata V; Acedo A; Sanz DJ; Velasco EA
PLoS Genet; 2017 Mar; 13(3):e1006691. PubMed ID: 28339459
[TBL] [Abstract][Full Text] [Related]
18. Splicing profile by capture RNA-seq identifies pathogenic germline variants in tumor suppressor genes.
Landrith T; Li B; Cass AA; Conner BR; LaDuca H; McKenna DB; Maxwell KN; Domchek S; Morman NA; Heinlen C; Wham D; Koptiuch C; Vagher J; Rivera R; Bunnell A; Patel G; Geurts JL; Depas MM; Gaonkar S; Pirzadeh-Miller S; Krukenberg R; Seidel M; Pilarski R; Farmer M; Pyrtel K; Milliron K; Lee J; Hoodfar E; Nathan D; Ganzak AC; Wu S; Vuong H; Xu D; Arulmoli A; Parra M; Hoang L; Molparia B; Fennessy M; Fox S; Charpentier S; Burdette J; Pesaran T; Profato J; Smith B; Haynes G; Dalton E; Crandall JR; Baxter R; Lu HM; Tippin-Davis B; Elliott A; Chao E; Karam R
NPJ Precis Oncol; 2020; 4():4. PubMed ID: 32133419
[TBL] [Abstract][Full Text] [Related]
19. Thorough in silico and in vitro cDNA analysis of 21 putative BRCA1 and BRCA2 splice variants and a complex tandem duplication in BRCA2 allowing the identification of activated cryptic splice donor sites in BRCA2 exon 11.
Baert A; Machackova E; Coene I; Cremin C; Turner K; Portigal-Todd C; Asrat MJ; Nuk J; Mindlin A; Young S; MacMillan A; Van Maerken T; Trbusek M; McKinnon W; Wood ME; Foulkes WD; Santamariña M; de la Hoya M; Foretova L; Poppe B; Vral A; Rosseel T; De Leeneer K; Vega A; Claes KBM
Hum Mutat; 2018 Apr; 39(4):515-526. PubMed ID: 29280214
[TBL] [Abstract][Full Text] [Related]
20. [The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition].
Moretta J; Berthet P; Bonadona V; Caron O; Cohen-Haguenauer O; Colas C; Corsini C; Cusin V; De Pauw A; Delnatte C; Dussart S; Jamain C; Longy M; Luporsi E; Maugard C; Nguyen TD; Pujol P; Vaur D; Andrieu N; Lasset C; Noguès C;
Bull Cancer; 2018 Oct; 105(10):907-917. PubMed ID: 30268633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
